BR0213026A - Compostos de imidazopiridina como reguladores do receptor 5-ht4 - Google Patents

Compostos de imidazopiridina como reguladores do receptor 5-ht4

Info

Publication number
BR0213026A
BR0213026A BR0213026-2A BR0213026A BR0213026A BR 0213026 A BR0213026 A BR 0213026A BR 0213026 A BR0213026 A BR 0213026A BR 0213026 A BR0213026 A BR 0213026A
Authority
BR
Brazil
Prior art keywords
hydrogen
alkyl
halo
arylalkyl
amido
Prior art date
Application number
BR0213026-2A
Other languages
English (en)
Inventor
David Roy Fenwick
Geofrey Edward Gymer
Hirohide Noguchi
Alan Stobie
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0213026A publication Critical patent/BR0213026A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTOS DE IMIDAZOPIRIDINA COMO REGULADORES DO RECEPTOR 5-HT~ 4~". A presente invenção proporciona um composto da fórmula (I): ou os sais farmaceuticamente aceitáveis deste, em que R^ 1^ é hidrogênio, halo ou alquilo; R^ 2^ e R^ 3^ são independentemente hidrogênio, alquilo, alcenilo, alcinilo, aminoalquilo ou hidroxi alquilo; ou R^ 2^ e R^ 3^ tomados em conjunto com o átomo de nitrogênio ao qual estão ligados podem formar um anel heterocíclico; R^ 4^ é hidrogênio, halo, acilo, amino, amido, arilo, arilalquilo ou heteroarilo; R^ 5^ é hidrogênio, halo, alquilo, alcenilo, alcinilo, acilo, amino, amido, arilo, arilalquilo ou heteroarilo; R^ 6^ é hidrogênio, alquilo ou alcoxi alquilo; X é NR^ 9^ em que R^ 9^ é hidrogênio ou alquilo; e Y é (CR^ 7^ R^ 8^)~ n~ em que n é um número inteiro de O a 5. Estes compostos possuem atividade de ligação ao receptor 5-HT~ 4~ e são, por isso, úteis para o tratamento do refluxo gastresofágico, dispepsia não ulcerosa, dispepsia funcional, síndrome do intestino irritável ou similares, em um mamífero, especialmente em seres humanos. A presente invenção proporciona também uma composição farmacêutica compreendendo os compostos acima.
BR0213026-2A 2001-10-22 2002-10-03 Compostos de imidazopiridina como reguladores do receptor 5-ht4 BR0213026A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34337101P 2001-10-22 2001-10-22
US41248502P 2002-09-20 2002-09-20
PCT/IB2002/004098 WO2003035649A1 (en) 2001-10-22 2002-10-03 Imidazopyridine compounds as 5-ht4 receptor modulators

Publications (1)

Publication Number Publication Date
BR0213026A true BR0213026A (pt) 2004-10-05

Family

ID=26993446

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213026-2A BR0213026A (pt) 2001-10-22 2002-10-03 Compostos de imidazopiridina como reguladores do receptor 5-ht4

Country Status (9)

Country Link
EP (1) EP1440071B1 (pt)
JP (1) JP2005526003A (pt)
AT (1) ATE307812T1 (pt)
BR (1) BR0213026A (pt)
CA (1) CA2461159A1 (pt)
DE (1) DE60206952T2 (pt)
ES (1) ES2248616T3 (pt)
MX (1) MXPA04002495A (pt)
WO (1) WO2003035649A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
BR0314584A (pt) * 2002-09-20 2005-08-09 Pfizer Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
CA2523077A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
DE102004024772A1 (de) * 2004-05-17 2005-12-22 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
WO2005118531A1 (en) * 2004-06-01 2005-12-15 Eli Lilly And Company Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake
JP5160764B2 (ja) * 2006-10-13 2013-03-13 全薬工業株式会社 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤
EP2096923B1 (en) 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroaryl amide derivatives
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
MY148461A (en) * 2007-04-10 2013-04-30 Lundbeck & Co As H Heteroaryl amide analogues as p2x7 antagonists
NZ720879A (en) 2013-12-16 2017-05-26 Suven Life Sciences Ltd Indazole compounds as 5-ht4 receptor agonists
US10570135B2 (en) 2014-11-06 2020-02-25 Lysosomal Therapeutics Inc. Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CN106146386A (zh) * 2015-04-21 2016-11-23 江苏威凯尔医药科技有限公司 一种制备普卡必利中间体的新工艺
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
AU2017261291C1 (en) 2016-05-05 2022-05-26 Bial - R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
DE60206952T2 (de) 2006-06-22
WO2003035649A1 (en) 2003-05-01
JP2005526003A (ja) 2005-09-02
EP1440071B1 (en) 2005-10-26
EP1440071A1 (en) 2004-07-28
ES2248616T3 (es) 2006-03-16
MXPA04002495A (es) 2004-05-31
CA2461159A1 (en) 2003-05-01
DE60206952D1 (de) 2005-12-01
ATE307812T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
BR0213026A (pt) Compostos de imidazopiridina como reguladores do receptor 5-ht4
BRPI0507180A (pt) derivados de 1-isopropil-2-oxo-1,2-diidropiridina-3-carboxamida tendo atividade agonìstica de receptor 5-ht4
AR036906A1 (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4
MXPA05011270A (es) Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3.
HUP0400828A2 (hu) Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0002461A2 (hu) Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
EA200700099A1 (ru) Производные пиридина
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
HUP0100388A2 (hu) Készítmények és eljárások csontritkulás kezelésére és a koleszterinszint csökkentésére
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
DE602004031722D1 (de) Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
DE60001586D1 (de) Diphenyl-piperidin derivate
NO20063562L (no) Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
RU2004130284A (ru) Антипаразитарные производные артемизинина (эндопероксиды)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008.